Spark Therapeutics Adds Chief Operating Officer to Management Team
December 05 2016 - 7:01AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company dedicated to challenging the inevitability of genetic
disease, today announced the appointment of John Furey to the newly
created position of chief operating officer. Mr. Furey will be
responsible for global commercial operations, medical affairs,
technology development and technical operations. He will report to
Jeffrey D. Marrazzo, chief executive officer, and will be an
executive officer of the company.
“Over the next few years, Spark Therapeutics will continue its
transformation into a global commercial company with the agility to
scale our commercial and manufacturing operations as needed to
bring our investigative gene therapies to patients around the
world,” said Mr. Marrazzo. “John brings a wide breadth of general
management experience gained while working in the U.S., Europe and
Asia, with deep expertise in commercial and manufacturing
operations, general management on the local and global level, as
well as global pricing and reimbursement. We are thrilled to add
John to our existing leadership team that will continue to lead
Spark’s transformation over the next few years.”
Mr. Furey has 25 years of experience in developing and
implementing operational strategies and leading commercial and
technical teams. Prior to joining Spark Therapeutics, he was senior
vice president and head
of global operations for Baxalta, where he
directed manufacturing, quality, engineering, and process
development. Mr. Furey actively managed a
$2.5 billion production budget across Baxalta's global
network and led a first-in-class supply chain organization for
rare diseases. He led the team that
coordinated and delivered the successful establishment of
Baxalta through a spin out from Baxter and led the Baxter
Vaccine inline business to realize significant top line
and bottom line growth. He also spent two years in China as
general manager of Pfizer’s vaccine business unit following a role
with responsibility for global pricing and reimbursement at Pfizer
Vaccines. In these roles, Mr. Furey gained extensive
experience in pipeline development and global product
launches. Earlier in his career, he held both
commercial and operations positions of increasing scope and
responsibility with Pfizer and Wyeth Pharmaceuticals. Mr.
Furey has an executive M.B.A. from St. Joseph’s University,
Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in
Environmental Health from the Dublin Institute of Technology.
About Spark TherapeuticsSpark Therapeutics, a
fully integrated company, is challenging the inevitability of
genetic disease by discovering, developing, and delivering gene
therapies that address inherited retinal diseases (IRDs),
liver-mediated diseases such as hemophilia, and neurodegenerative
diseases. Our validated platform successfully has delivered
proof-of-concept data with investigational gene therapies in the
retina and liver. Our most advanced investigational candidate,
voretigene neparvovec, in development for the treatment of
RPE65-mediated IRD, has received orphan designations in the U.S.
and European Union, and breakthrough therapy designation in the
U.S. The pipeline also includes SPK-7001, in a Phase 1/2 trial for
choroideremia, and two hemophilia development programs: SPK-9001 in
a Phase 1/2 trial for hemophilia B being developed in collaboration
with Pfizer (which also has received both breakthrough therapy and
orphan product designations) and SPK-8011, a preclinical candidate
for hemophilia A to which Spark Therapeutics retains global
commercialization rights. To learn more about us and our growing
pipeline, visit www.sparktx.com.
Spark Therapeutics Corporate Contacts
Stephen W. Webster, Chief Financial Officer
Daniel Faga, Chief Business Officer
(855) SPARKTX (1-855-772-7589)
Media Contact
Dan Quinn
Ten Bridge Communications
(781) 475-7974
dan@tenbridgecommunications.com
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Apr 2023 to Apr 2024